Noshaq
Noshaq is a venture capital firm based in Liège, Belgium, founded in 1985. It provides seed, startup and growth capital to small and medium-sized companies, with a focus on the Liège region. The portfolio covers sectors such as energy, sustainable development, biotech, digital, Industry 4.0, real estate, quality food, cultural and creative industries, life sciences, agriculture and food, and reconversion. Noshaq typically takes a minority stake and may secure a seat on the board. In addition to equity investments, the firm offers convertible bonds, financing solutions, loans and support for strategic projects.
Top Stages
4 past transactions
ARK Capture Solutions
Pre Seed Round in 2025
ARK Capture Solutions is a cleantech company that specializes in providing affordable and versatile decarbonization services. It offers advanced carbon capture technology, designed to efficiently handle low CO₂ concentrations in flue gas, thereby enabling its clients to significantly reduce their carbon dioxide emissions while minimizing energy consumption.
Pleevi
Pre Seed Round in 2025
Pleevi specializes in optimizing electric vehicle (EV) charging for large parking facilities. It provides an AI-driven software solution that intelligently schedules charging sessions, considering local energy generation, pricing, and building load constraints. This ensures cheaper, greener charging while maintaining driver convenience, as vehicles are fully charged by the time drivers are ready to depart.
I-care Group
Series C in 2024
Founded in Belgium in 2004, I-care Group specializes in predictive and prescriptive maintenance for industries. It optimizes industrial risk management through data collection, analysis, and AI-powered predictions to enhance business performance, safety, and environmental sustainability.
Signatur Biosciences
Signatur Biosciences is a biotechnology company focused on molecular diagnostics for cancer. It develops a PCR-based testing platform that condenses the detection and interpretation of a panel of RNA biomarkers into a single test, aiming to make precision diagnostics more accessible. The company offers a smart kit compatible with existing PCR machines and off-the-shelf reagents, enabling integration with current clinical workflows and infrastructure in oncology care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.